{Reference Type}: Journal Article
{Title}: Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease.
{Author}: Salva-Pastor N;Chávez-Tapia NC;Uribe M;Nuño-Lámbarri N;
{Journal}: J Steroid Biochem Mol Biol
{Volume}: 194
{Issue}: 0
{Year}: 11 2019
{Factor}: 5.011
{DOI}: 10.1016/j.jsbmb.2019.105445
{Abstract}: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-age women. Patients with non-alcoholic fatty liver disease (NAFLD) often suffer from metabolic syndrome, atherosclerosis, ischemic heart disease, and extrahepatic tumors, conferring a lower survival than the general population; therefore it is crucial to study the association between NAFLD and PCOS since it remains poorly understood. Insulin resistance (IR) plays a central role in the pathogenesis of NAFLD and PCOS; also, hyperandrogenism enhances IR in these patients. IR, present in the NAFLD-PCOS association could decrease the hepatic production of sex hormone-binding globulin through a possible regulation mediated by hepatocyte nuclear factor 4 alpha. On the other hand, apoptotic processes initiated by androgens actively contribute to the progression of NAFLD. Considering the association between the two conditions, the screening of women with PCOS for the presence of NAFLD appears reasonable. The pathophysiological mechanisms of PCOS-NAFLD association and the initial approach will be reviewed here.